Role of paliperidone extended-release in treatment of schizoaffective disorder

Carla M Canuso1, Ibrahim Turkoz2, Dong Jing Fu3, Cynthia A Bossie31External Innovation Neuroscience Therapeutic Area, 2Biostatistics, Johnson &amp; Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA; 3CNS Medical Affairs, Ortho-McNeil Janssen Scientific Affairs, LLC, T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carla M Canuso, Ibrahim Turkoz, Dong Jing Fu, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/adcc3cc9eec44cc5bcc3b18f4f62850a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:adcc3cc9eec44cc5bcc3b18f4f62850a
record_format	dspace
spelling	oai:doaj.org-article:adcc3cc9eec44cc5bcc3b18f4f62850a2021-12-02T07:14:23ZRole of paliperidone extended-release in treatment of schizoaffective disorder1176-63281178-2021https://doaj.org/article/adcc3cc9eec44cc5bcc3b18f4f62850a2010-09-01T00:00:00Zhttp://www.dovepress.com/role-of-paliperidone-extended-release-in-treatment-of-schizoaffective--a5390https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Carla M Canuso1, Ibrahim Turkoz2, Dong Jing Fu3, Cynthia A Bossie31External Innovation Neuroscience Therapeutic Area, 2Biostatistics, Johnson &amp; Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA; 3CNS Medical Affairs, Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USAAbstract: Schizoaffective disorder is characterized by the presence of symptoms of both schizophrenia and a major mood disorder. The coexistence of these symptoms can be difficult to manage, and these patients are generally treated with antipsychotics as well as mood stabilizers and/or antidepressants. Additionally, no established treatment guidelines exist for this disorder. This review describes the combined results of two international, double-blind, placebo-controlled clinical studies of paliperidone extended-release (ER), an atypical antipsychotic recently approved in the US for the treatment of schizoaffective disorder. Subjects in these six-week trials were aged 18&ndash;65 years, had a diagnosis of schizoaffective disorder based on the Structural Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) Disorders, and were experiencing an acute exacerbation. The subjects from these studies had significant symptomatology as evidenced by a mean (standard deviation) baseline Positive and Negative Syndrome Scale total score of 92.8 (13.0). Based on Young Mania Rating Scale and/or a 21-item Hamilton Rating Scale for Depression score of &ge;16 at baseline, 79.5% and 66.9% of subjects presented with prominent manic and depressive symptoms, respectively, and 46.4% presented with mixed symptoms. Approximately half (45%) of subjects were taking adjunctive mood stabilizers and/or antidepressants. Paliperidone ER was found to be effective in improving psychotic and mood symptoms in these subjects. Paliperidone ER was also effective as monotherapy or adjunctive to mood stabilizers and/or antidepressants for subjects with prominent manic, depressive, or mixed symptoms at baseline. No new tolerability signals were observed in this population. To the best of our awareness, these pooled data provide the largest data set of patients with schizoaffective disorder, and extend our knowledge of disease characteristics and treatment response.Keywords: paliperidone extended-release, antipsychotic, schizoaffective disorder Carla M CanusoIbrahim TurkozDong Jing Fuet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 667-679 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Carla M Canuso Ibrahim Turkoz Dong Jing Fu et al Role of paliperidone extended-release in treatment of schizoaffective disorder
description	Carla M Canuso1, Ibrahim Turkoz2, Dong Jing Fu3, Cynthia A Bossie31External Innovation Neuroscience Therapeutic Area, 2Biostatistics, Johnson &amp; Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA; 3CNS Medical Affairs, Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USAAbstract: Schizoaffective disorder is characterized by the presence of symptoms of both schizophrenia and a major mood disorder. The coexistence of these symptoms can be difficult to manage, and these patients are generally treated with antipsychotics as well as mood stabilizers and/or antidepressants. Additionally, no established treatment guidelines exist for this disorder. This review describes the combined results of two international, double-blind, placebo-controlled clinical studies of paliperidone extended-release (ER), an atypical antipsychotic recently approved in the US for the treatment of schizoaffective disorder. Subjects in these six-week trials were aged 18&ndash;65 years, had a diagnosis of schizoaffective disorder based on the Structural Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) Disorders, and were experiencing an acute exacerbation. The subjects from these studies had significant symptomatology as evidenced by a mean (standard deviation) baseline Positive and Negative Syndrome Scale total score of 92.8 (13.0). Based on Young Mania Rating Scale and/or a 21-item Hamilton Rating Scale for Depression score of &ge;16 at baseline, 79.5% and 66.9% of subjects presented with prominent manic and depressive symptoms, respectively, and 46.4% presented with mixed symptoms. Approximately half (45%) of subjects were taking adjunctive mood stabilizers and/or antidepressants. Paliperidone ER was found to be effective in improving psychotic and mood symptoms in these subjects. Paliperidone ER was also effective as monotherapy or adjunctive to mood stabilizers and/or antidepressants for subjects with prominent manic, depressive, or mixed symptoms at baseline. No new tolerability signals were observed in this population. To the best of our awareness, these pooled data provide the largest data set of patients with schizoaffective disorder, and extend our knowledge of disease characteristics and treatment response.Keywords: paliperidone extended-release, antipsychotic, schizoaffective disorder
format	article
author	Carla M Canuso Ibrahim Turkoz Dong Jing Fu et al
author_facet	Carla M Canuso Ibrahim Turkoz Dong Jing Fu et al
author_sort	Carla M Canuso
title	Role of paliperidone extended-release in treatment of schizoaffective disorder
title_short	Role of paliperidone extended-release in treatment of schizoaffective disorder
title_full	Role of paliperidone extended-release in treatment of schizoaffective disorder
title_fullStr	Role of paliperidone extended-release in treatment of schizoaffective disorder
title_full_unstemmed	Role of paliperidone extended-release in treatment of schizoaffective disorder
title_sort	role of paliperidone extended-release in treatment of schizoaffective disorder
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/adcc3cc9eec44cc5bcc3b18f4f62850a
work_keys_str_mv	AT carlamcanuso roleofpaliperidoneextendedreleaseintreatmentofschizoaffectivedisorder AT ibrahimturkoz roleofpaliperidoneextendedreleaseintreatmentofschizoaffectivedisorder AT dongjingfu roleofpaliperidoneextendedreleaseintreatmentofschizoaffectivedisorder AT etal roleofpaliperidoneextendedreleaseintreatmentofschizoaffectivedisorder
_version_	1718399532804341760

Role of paliperidone extended-release in treatment of schizoaffective disorder

Ejemplares similares